Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 2292-2296, November 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loos, M.
Right arrow Articles by Goldin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loos, M.
Right arrow Articles by Goldin, A.

Detection of Endotoxin in Commercial L-Asparaginase Preparations by Complement Fixation and Separation by Chromatography

M. Loos1, S. Vadlamudi, M. Meltzer, S. Shifrin, T. Borsos2 and A. Goldin

Institute of Medical Microbiology, J. Gutenberg University, D-65 Mainz, Germany [M. L.]; Microbiological Associates, Inc., Bethesda, Maryland 20014 [S. V.]; and Viral Leukemia and Lymphoma Branch, Laboratory of Cell Biology [S. S.], Biology Branch [T. B.], and Drug Research and Development, Chemotherapy [A. G.], National Cancer Institute, Bethesda, Maryland 20014

Of 15 L-asparaginase preparations tested, 13 inhibited whole human serum complement; the inhibitory effect ranged from 12 to 45%. We have partially characterized the anticomplementary activity in one of the L-asparaginase preparations. The anticomplementary activity was separable from the L-asparaginase activity on Sephadex G-200. Fractions containing L-asparaginase had no effect either on whole human serum complement or on human serum C1, the first component of complement; these fractions were therapeutic in leukemic mice. Fractions containing the anticomplementary activity had no significant therapeutic effect in leukemic mice. L-asparaginase and the anticomplementary factor are antigenically distinct, and the anticomplementary factor was shown to be antigenically related to Escherichia coli lipopolysaccharide (endotoxin).

1 Guest worker in the Biology Branch, National Cancer Institute. Supported by the Deutsche Forschungsgemeinschaft Lo 188/1.

2 To whom reprint requests should be sent, at National Cancer Institute, Building 37, Room 2B15, Bethesda, Md. 20014.

Received 5/31/72. Accepted 7/12/72.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. B. Reinert, L. M. Oberle, S. A. Wek, P. Bunpo, X. P. Wang, I. Mileva, L. O. Goodwin, C. J. Aldrich, D. L. Durden, M. A. McNurlan, et al.
Role of Glutamine Depletion in Directing Tissue-specific Nutrient Stress Responses to L-Asparaginase
J. Biol. Chem., October 20, 2006; 281(42): 31222 - 31233.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.